Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared a post on LinkedIn:
“Our new paper is out and I think it fills a real gap in brain metastasis trial design.
I’m proud to share our multi-institutional study, just published in Neuro-Oncology: the first systematic evaluation of the Breast Graded Prognostic Assessment (Breast GPA) as a predictor of intracranial progression-free survival (icPFS) in breast cancer brain metastases.
Why we did this: When designing trials for patients with breast cancer brain metastases (BCBM), one of the hardest questions is: what do we power against? icPFS is increasingly recognized as a meaningful, measurable endpoint – but robust historical benchmarks, stratified by subtype and GPA, simply didn’t exist. We built this study to change that. What we found (2,263 patients, 17 institutions):
- The Breast GPA – already validated for overall survival – also predicts icPFS. Median icPFS ranged from 5 months (GPA 0.0–1.0) to 13 months (GPA 3.5-4.0)
icPFS varies substantially by tumor subtype:
- HR+/HER2+: 12 months
- HR-/HER2+: 10 months
- HR+/HER2-: 8 months
- Triple-negative (TNBC): 6 months
- icPFS and OS are strongly correlated (r = 0.783) – supporting icPFS as a viable surrogate endpoint that can accelerate how we evaluate novel therapies
- The strongest predictors of icPFS were tumor subtype, KPS, and number of brain metastases not the radiation modality used (SRS vs. WBRT).”
Title: Intracranial Progression-Free Survival Correlates with Overall Survival and Varies by Tumor Subtype in Patients with Breast Cancer and Brain Metastases
Authors: Sarah L Sammons ,Ryan Shanley ,Carey K Anders ,Nancy U Lin ,Paul W Sperduto
Read the full article on Neuro-Oncology.
Other articles about Breast Cancer on OncoDaily.